{"id":"W1828063937","doi":"10.1007/s40121-015-0071-0","title":"Cost-Effectiveness of Dolutegravir in HIV-1 Treatment-Naive and Treatment-Experienced Patients in Canada","year":2015,"lang":"en","type":"article","venue":"Infectious Diseases and Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"ca_institutions":"GlaxoSmithKline (Canada)","funders":"ViiV Healthcare","keywords":"Dolutegravir; Medicine; Atazanavir; Ritonavir; Raltegravir; Elvitegravir; Efavirenz; Rilpivirine; Abacavir; Cost effectiveness; Darunavir; Cobicistat; Adverse effect; Internal medicine; Human immunodeficiency virus (HIV); Viral load; Virology; Antiretroviral therapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001332415,0.0004648345,0.0005880063,0.0005783637,0.0007956393,0.001229859,0.0009239162,0.0005100877,0.002235638],"category_scores_gemma":[0.004753422,0.0002763085,0.001119416,0.0009712087,0.0004936052,0.0003254808,0.000637051,0.0005992008,0.00009385296],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.04419725,"about_ca_system_score_gemma":0.03441158,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.952028,"about_ca_topic_score_gemma":0.9310099,"domain_scores_codex":[0.999262,0.0002241865,0.00002839819,0.00007336675,0.000171773,0.0002403101],"domain_scores_gemma":[0.9984255,0.000626187,0.0001905863,0.00003678856,0.000383373,0.0003376202],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"simulation_or_modeling","study_design_gemma":"observational","study_design_scores_codex":[0.004958444,0.0005254842,0.2410903,0.0005200565,0.001385865,0.0005700221,0.0002508888,0.7011985,0.000670128,0.0059845,0.004306376,0.03853948],"study_design_scores_gemma":[0.002025431,0.00138957,0.1676743,0.0003292316,0.0009345811,0.000340624,0.0007075131,0.8175319,0.0008897175,0.002954797,0.005115464,0.0001068731],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9841419,0.002946951,0.001550494,0.001343184,0.00002431539,0.0002265933,0.003240356,0.00004722801,0.006479034],"genre_scores_gemma":[0.9970165,0.0005529177,0.0008060071,0.0001186963,0.000004491645,0.00002866105,0.000919324,0.000005512601,0.0005478624],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.04797202,"threshold_uncertainty_score":0.320675,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02564710316898824,"score_gpt":0.2825397717375404,"score_spread":0.2568926685685522,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}